AEZS-130 patent came into effect from 19 September 2012 and will be valid till 19 February 2027.
Aeterna Zentaris president and CEO Juergen Engel said the patent in Europe and US are key elements to ensure the protection of AEZS 130 to diagnose GHD.
”We now look forward to filing a New Drug Application in the near future in the U.S. for AEZS-130, which could become the first approved oral diagnostic test for adults with GHD," Engel added.
AEZS-130 is a new oral active small molecule, which stimulates the secretion of growth hormone.
Adult Growth Hormone Deficiency affects nearly 35,000 US citizens along with 6,000 new cases each year.